Stock Events

Stock Events

Alterity Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugExpected
Q4 2025
Next
-0.03
-0.02
-0.01
-0.01
Expected EPS
-0.009486965241710001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.06MNet Income

Analyst Ratings

9.86Average Price Target
The highest estimate is 12.14.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBNN.MU. It's not an investment recommendation.
Apple
5
AAPL
Tesla
4
TSLA
Amazon
4
AMZN
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap17.79M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.97B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap231.68M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap12.03B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap483.74M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap207.85M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Show more...
CEO
Mr. Geoffrey Paul Kempler B.Sc.
Employees
11
Country
Australia
ISIN
US02155X1063

Listings

AU
AU
ATH.AU
MU
DE
PBNN.MU
STU
DE
PBN.STU
OTCM
US
PRNAD

0 Comments

Share your thoughts

FAQ

What is Alterity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Alterity Therapeutics stocks are traded under the ticker PBNN.MU.
When is the next Alterity Therapeutics earnings date?▼
Alterity Therapeutics is going to release the next earnings report on August 28, 2026.
What were Alterity Therapeutics earnings last quarter?▼
PBNN.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.02 EUR resulting in a -56.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Alterity Therapeutics revenue for the last year?▼
Alterity Therapeutics revenue for the last year amounts to 0 EUR.
What is Alterity Therapeutics net income for the last year?▼
PBNN.MU net income for the last year is -7.06M EUR.
How many employees does Alterity Therapeutics have?▼
As of July 22, 2026, the company has 11 employees.
In which sector is Alterity Therapeutics located?▼
Alterity Therapeutics operates in the Health & Wellness sector.
When did Alterity Therapeutics complete a stock split?▼
The last stock split for Alterity Therapeutics was on January 09, 2023 with a ratio of 1:10.
Where is Alterity Therapeutics headquartered?▼
Alterity Therapeutics is headquartered in Melbourne, Australia.